Search results
Showing 271 to 285 of 529 results for drug monitoring
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.
Transient loss of consciousness ('blackouts') in over 16s (QS71)
This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.
View quality statements for QS71Show all sections
Sections for QS71
- Quality statements
- Quality statement 1: Initial assessment – recording the event, clinical history and physical examination
- Quality statement 2: Initial assessment – 12-lead electrocardiogram (ECG)
- Quality statement 3: Urgent specialist cardiovascular assessment within 24 hours of the initial assessment
- Quality statement 4: Initial assessment – unnecessary use of electroencephalogram (EEG)
- Quality statement 5: Driving advice
- Quality statement 6: Specialist cardiovascular investigation – ambulatory electrocardiogram (ECG)
- Update information
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)
Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
Prucalopride for the treatment of chronic constipation in women (TA211)
Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women.
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.
This guideline covers contraceptive services for under-25s. It aims to ensure all under-25s are given advice and information on all types of contraception. This includes additional tailored support to meet the particular needs and choices of those who are socially disadvantaged or who may find it difficult to use these services.
View recommendations for PH51Show all sections
Type 2 diabetes prevention: population and community-level interventions (PH35)
This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.